Patents Assigned to Bethesda Pharmaceuticals, Inc.
-
Publication number: 20120094913Abstract: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes.Type: ApplicationFiled: December 8, 2011Publication date: April 19, 2012Applicant: Bethesda Pharmaceuticals, Inc.Inventor: Harrihar A. PERSHADSINGH
-
Publication number: 20110046188Abstract: Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating or preventing conditions comprising hypertension and dyslipidemia, comprising antihyperlipemic agents which lower triglycerides and inhibit cholesterol synthesis such as statins, and compounds that antagonize or block the angiotensin II type 1 (AT1) receptor, activate PPARs and lower triglycerides or elevate blood HDL-cholesterol such as sartans.Type: ApplicationFiled: October 29, 2010Publication date: February 24, 2011Applicant: Bethesda Pharmaceuticals, Inc.Inventor: Harrihar A. PERSHADSINGH
-
Patent number: 7867991Abstract: Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating or preventing conditions comprising hypertension and dyslipidemia, comprising antihyperlipemic agents which lower triglycerides and inhibit cholesterol synthesis such as statins, and compounds that antagonize or block the angiotensin II type 1 (AT1) receptor, activate PPARs and lower triglycerides or elevate blood HDL-cholesterol such as sartans.Type: GrantFiled: November 10, 2006Date of Patent: January 11, 2011Assignee: Bethesda Pharmaceuticals, Inc.Inventor: Harrihar A. Pershadsingh
-
Patent number: 7812046Abstract: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes.Type: GrantFiled: April 27, 2007Date of Patent: October 12, 2010Assignee: Bethesda Pharmaceuticals, Inc.Inventor: Harrihar A. Pershadsingh
-
Patent number: 7339065Abstract: This invention provides new chemical entities useful for treating a variety of clinical disorders including those that are influenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5adamantan-2-yl-pentanoic acid {2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.Type: GrantFiled: July 21, 2004Date of Patent: March 4, 2008Assignees: Bethesda Pharmaceuticals, Inc., The University of MississippiInventors: Mitchell A. Avery, Harrihar A. Pershadsingh
-
Publication number: 20070185070Abstract: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes.Type: ApplicationFiled: April 6, 2007Publication date: August 9, 2007Applicant: Bethesda Pharmaceuticals, Inc.Inventor: Harrihar Pershadsingh
-
Patent number: 7232828Abstract: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes.Type: GrantFiled: July 24, 2003Date of Patent: June 19, 2007Assignee: Bethesda Pharmaceuticals, Inc.Inventor: Harrihar A. Pershadsingh
-
Patent number: 6664287Abstract: This invention comprises administering to a human or animal in need of treatment an effective amount of an antioxidant lipoic acid derivative and/or pharmaceutically acceptable salts and solvates thereof for the treatment or prevention of pathological (inflammatory, proliferative and degenerative diseases, e.g. diabetes mellitus, atherosclerosis, Alzheimer's disease and chronic viral diseases) and non-pathological (e.g. skin aging and wrinkle formation) conditions caused by oxidative damage. Methods of synthesizing novel antioxidant lipoic acid derivatives and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are described. Another aspect of this invention is the use of these antioxidant compositions for the protection of skin from damage caused by ultraviolet radiation and dessication, and to provide improved skin feel by desquamating, cleansing and clarifying the skin.Type: GrantFiled: March 14, 2001Date of Patent: December 16, 2003Assignee: Bethesda Pharmaceuticals, Inc.Inventors: Mitchell Allen Avery, Harrihar A. Pershadsingh
-
Patent number: 6369098Abstract: The present invention describes methods for synthesizing novel dithiolane derivatives, ligands with high affinity for the nuclear hormone receptors, peroxisome proliferator-activated receptor-&ggr; (PPAR&ggr;) and/or PPAR&agr;. Methods for using these compounds in the treatment of endocrine, skin, cardiovascular, immunological, neurological, neuropsychiatric, neoplastic and chronic viral diseases of various organs, including the eye are described. Methods of treating proliferative and inflammatory diseases, degenerative diseases, and age-related dysregulations, caused by an hereditary (genetic) condition or an environmental insult are also provided.Type: GrantFiled: October 4, 2000Date of Patent: April 9, 2002Assignee: Bethesda Pharmaceuticals, Inc.Inventors: Harrihar A. Pershadsingh, Mitchell A. Avery
-
Patent number: 5824694Abstract: A new medical use for certain thiazolidine derivatives is disclosed. Specifically, treatment of hyperproliferative epithelial cell conditions, such as psoriasis, by administration of thiazolidinediones or 5'-aryl substituted thiazolidine derivatives is described. Appropriate chemical structures, synthetic reactions, formulations, routes of administration and dosages are included.Type: GrantFiled: April 18, 1996Date of Patent: October 20, 1998Assignee: Bethesda Pharmaceuticals, Inc.Inventors: Theodore W. Kurtz, Harrihar A. Pershadsingh